A clinical first-line drug and an industry-leading product for the treatment of anemia in many fields
EPOSINO is the first batch of human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, the Philippines and Indonesia.
● Anemia caused by renal dysfunction, including dialysis and non-dialysis patients;
● Perioperative erythrocyte mobilization;
● Anemia caused by chemotherapy for non-myeloid malignancies. (To be added)